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Hyaluronan (HA) is a non-sulfated glycosaminoglycan distributed throughout the extracel-
lular matrix that plays a major role in cell adhesion, migration, and proliferation. CD44, a
multifunctional cell surface glycoprotein, is a receptor for HA. In addition, CD44 is known
to interact with other receptors and ligands, and to mediate a number of cellular functions
as well as disease progression. Studies have shown that binding of HA to CD44 in can-
cer cells activates survival pathways resulting in cancer cell survival. This effect can be
blocked by anti-CD44 monoclonal antibodies. A6 is a capped, eight L-amino acid peptide
(Ac-KPSSPPEE-NH2) derived from the biologically active connecting peptide domain of the
serine protease, human urokinase plasminogen activator (uPA). A6 neither binds to the
uPA receptor (uPAR) nor interferes with uPA/uPAR binding. A6 binds to CD44 resulting in
the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of
CD44-mediated cell signaling. A6 has been shown to have no dose-limiting toxicity in animal
studies. A6 has demonstrated efficacy and an excellent safety profile in Phase 1a, 1b, and
2 clinical trials. In animal models, A6 has also exhibited promising results for the treatment
of diabetic retinopathy and wet age-related macular degeneration through the reduction
of retinal vascular permeability and inhibition of choroidal neovascularization, respectively.
Recently, A6 has been shown to be directly cytotoxic for B-lymphocytes obtained from
patients with chronic lymphocytic leukemia expressing the kinase, ZAP-70. This review
will discuss the activity of A6, A6 modulation of HA and CD44, and a novel strategy for
therapeutic intervention in disease.
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INTRODUCTION
Mortality due to cancer is generally the result of metastasis of
the primary tumor. Recurrence at distant sites following first-line
therapy continues to be a major challenge. As a result, drugs that
inhibit the metastatic process are of great interest. Metastasis and
recurrence have been linked to a subpopulation of highly invasive
tumorigenic cells that are characterized by the expression of CD44.
A6 has been shown to bind to CD44 and to exhibit anti-metastatic
properties. Thus, A6 may serve as a therapeutic alternative for the
treatment and prevention of metastatic disease.
A6 BACKGROUND
A6 is a capped eight l-amino acid peptide (Ac-KPSSPPEE-NH2)
derived from amino acid residues 136–143 of the connecting
peptide domain of human urokinase plasminogen activator (uPA).
The connecting peptide domain is located between the N-
terminal growth factor domain and the C-terminal catalytic
domain of uPA (Figure 1). The N-terminal growth factor domain
of uPA binds to the uPA receptor (uPAR) to initiate the uPA/uPAR
cascade, which is catalyzed by the C-terminal serine protease that
activates plasminogen to plasmin. Numerous studies have shown
that the binding of uPA to uPAR, initiates a cascade of events lead-
ing to proteolysis, degradation of the extracellular matrix (ECM),
cell migration, cell invasion, metastasis, and angiogenesis (1–4).
Further, the uPA system has been shown to play an important
role in the growth and spread of solid tumors. Levels of uPA and
uPAR correlate with clinical outcome in a variety of malignan-
cies. Specifically, the upregulation of the uPA system is associated
with poor prognosis, and inhibition of the uPA system has been
shown to block critical processes (e.g., cell migration, invasion,
and angiogenesis) required for a broad range of proliferative dis-
eases. This provides the rationale for development of inhibitors of
this pathway (5–9).
The binding of uPA to uPAR has been localized to the N-
terminal growth factor domain. Although the growth factor
domain is known to initiate biological activity, the connecting
peptide domain of uPA has also been shown to have biological
activity independent of the growth factor domain (10, 11). uPA has
been shown to bind to HEK 293 cells (transformed with uPAR) to
stimulate migration (10). The binding of uPA peptide fragments
composed of the growth factor domain and connecting peptide
domain were evaluated to characterize domain-specific activity
on the cell surface (10). Both the growth factor and connecting
peptide domains were capable of stimulating cell migration inde-
pendently. Furthermore, the binding of these peptide fragments
to HEK 293 cells was inhibited by increasing concentrations of
the uPA molecule. However, the connecting peptide domain itself
did not inhibit growth factor domain binding, and growth fac-
tor domain did not inhibit connecting peptide domain binding.
This indicated the presence of distinct binding sites for both the
growth factor domain and connecting peptide domain, as well as a
uPAR-independent signaling pathway (10). It was postulated that
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FIGURE 1 | Schematic representation of urokinase plasminogen activator (uPA) domains illustrating the location of A6.
FIGURE 2 | Serine 138 of uPA is included in the A6-peptide sequence.
the connecting peptide domain of uPA was functioning through
interaction with a cell surface integrin receptor (10, 11).
The biological importance of the connecting peptide domain
(amino acid residues 132–158) has been further demonstrated by
the phosphorylation or substitution of serine 138, which results
in the inhibition of uPA-induced cell migration without changing
uPA binding to uPAR (12, 13). A6 comprises uPA amino acids 136–
143. The serine 138 residue of uPA is included in the A6 sequence
(Figure 2).
Phosphorylation or substitution of uPA serine 138 does not
change the growth factor domain-mediated binding of uPA to
uPAR, yet inhibits migration, which suggests that the connect-
ing peptide domain region is important for regulatory function.
This indicates that simultaneous concurrent interaction of uPA
domains, with distinct surface receptors, is required for uPAR-
dependent cell migration. This provided additional evidence to
support the investigation of the A6-peptide.
The biological activity localized within the uPA connecting pep-
tide domain prompted additional study. It was postulated that
proteolysis by plasmin and matrix metalloproteinases (MMPs)
such as MMP3 and MMP7 could excise a fragment from amino
acids 136–143, corresponding to A6. Although there is no evidence
that this proteolytic processing occurs, several peptides compris-
ing various fragments of the connecting peptide domain sequence
were synthesized. The A6 sequence was found to have activity,
which led to the preclinical and clinical investigation of A6.
Interestingly, A6 shares sequence homology with a portion
of the link domain of CD44 (CD44 amino acid residues 120-
NASAPPEE-127) (14) (Figure 3). The CD44 gene is encoded by
FIGURE 3 | A comparison of the sequence homology betweenA6 and
amino acid residues 120–127 of the CD44 link domain.
20 exons in the mouse and 19 exons in humans: 5 constant exons
are expressed at the 5′ end, and 10 variant exons (mouse) or 9
variant exons (human) may be alternatively spliced within CD44
at an insertion site after the fifth constitutive exon, followed by
the remaining constant exons at the 3′ end (15, 16). The stan-
dard isoform of CD44 (CD44s) is the smallest isoform containing
no variant exons, and the largest is CD44v1–10, which contains
all of the variant exons. Although a CD44 isoform specificity
has not been determined for A6, it is important to note that the
region of A6 sequence homology in CD44, through which A6 may
act, is conserved in all CD44 isoforms as it is located within the
first five non-variable exons of the molecule (15). This homol-
ogy is important because the sequence straddles the CD44 splice
junction of exons 3 and 4, includes a potential glycosylation site,
and is involved with hyaluronan (HA) binding (14, 15, 17–21).
The evaluation of A6 activity using alanine scanning mutagene-
sis demonstrated that there is a degree of substitution that can be
accommodated without a substantial loss of A6 activity, and analy-
sis of the CD44 homologous peptide sequence revealed activity
similar to that of A6 (22).
A6 AND METASTATIC DISEASE
PRECLINICAL STUDIES
Preclinical studies have shown that A6 has anti-migratory, anti-
invasive, and anti-metastatic properties. A6 has been shown to
inhibit migration and invasion of breast, lung, glioma, ovarian,
and prostate cancer cell lines in vitro in a dose-dependent man-
ner (23–27), and to inhibit the growth and metastasis of breast,
melanoma, glioma, lung, and prostate cancer cells in xenograft
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models in vivo (14, 24–27). Interestingly, the combination of A6
with tamoxifen resulted in an inhibition of breast tumor cell
growth greater than with either A6 or tamoxifen alone (24). A
similar result was observed in glioma xenograft studies where
the combination of A6 with cisplatin also inhibited tumor cell
growth greater than with either A6 or cisplatin alone (26). These
results are important because of the relationship between CD44
and chemoresistance.
IN VITRO STUDIES
Boyden chamber analyses demonstrated that A6 inhibited chemo-
taxis in a variety of human breast and ovarian cancer cell lines in
a concentration-dependent manner (14). The IC50 for the inhi-
bition of chemotaxis of responsive cell lines was 10–100 nmol/L
suggesting physiological relevance (14). Furthermore, A6 inhibi-
tion of chemotaxis was shown to correlate with the expression of
CD44. This was demonstrated by flow cytometric analysis with
four different anti-CD44 antibodies and five different human
ovarian cancer cell lines. A6 produced more than 85% inhibi-
tion of migration in CD44-positive SKOV3 cells when compared
to untreated control (14). Notably, A6 had no effect on the migra-
tion of CD44-negative A2780 cells. A6 was also shown to interfere
with the binding of only one (DF1485) of the four anti-CD44
antibodies tested (14). A6 did not interfere with the binding of
the anti-CD44 antibody, IM7, which blocks HA binding to CD44.
These findings suggest that A6 does not produce a global non-
specific change in CD44, but instead produces a subtle change to
a specific epitope.
Because A6 inhibited migration of SKOV3 cells, this study also
examined the direct interaction of A6 with CD44 (14). Human
ovarian SKOV3 cells were bound and cross-linked to A6. Immuno-
precipitation and immunoblotting of lysate preparations of cross-
linked cells revealed that A6 was binding to CD44. To determine
if this binding influenced CD44-mediated activity, and to deter-
mine if a functional relationship existed between A6 and CD44,
intracellular signaling studies were conducted. A6 was shown to
modulate FAK phosphorylation in CD44-positive SKOV3 cells,
but not in CD44-negative A2780 cells. The study further demon-
strated that the A6 modulation of FAK phosphorylation in SKOV3
cells was blocked by HA. These results show that a functional rela-
tionship exists between A6 and CD44 binding and CD44-mediated
intracellular signaling (14).
IN VIVO STUDIES
Mammary
The effects of A6 in mammary tumor and metastasis mod-
els have been investigated. Studies with BALB/c (nu/nu) mice
implanted with MDA-MB-231 human mammary carcinoma
xenografts demonstrated that A6 inhibited tumor growth by 90%
compared to control (23). An inhibition of metastasis was also
noted. Additionally, the effect of A6 in Fisher rats inoculated
with Mat B-III syngeneic mammary carcinoma cells was evalu-
ated. A6 treatment inhibited tumor growth by 55% and markedly
suppressed lymph node metastasis (23). Furthermore, the com-
bination of A6 with tamoxifen in Fisher rats with Mat B-III
syngeneic mammary carcinoma resulted in a 75% inhibition of
tumor growth (24).
Prostate
A model of prostate cancer was used to evaluate the anti-metastatic
effect of A6 in mice. Metastases to lymph nodes were measured
following the orthotopic injection of human PC-3M-LN4 prostate
cancer cells into the prostates of BALB/c (nu/nu) mice. The per-
centage of mice with lymph node metastases was reduced from
more than 70% in the control group to as low as 22% in A6-treated
animals (27). Additionally, A6 treatment significantly reduced
lymph node volume by as much as 70%.
Glioblastoma
In animal models of glioblastoma, U87MG human glioma cells
were implanted subcutaneously or intracranially in BALB/c
(nu/nu) mice and the animals were divided into different treat-
ment groups. A6 treatment suppressed subcutaneous U87MG
tumor growth by 48% and prolonged the time to progression
(TTP) following discontinuation of A6 treatment (26). In this
study, the effects of cisplatin were also examined. Cisplatin treat-
ment reduced tumor growth by 53%. Interestingly, the combina-
tion of A6 and cisplatin resulted in a 92% inhibition of subcuta-
neous tumor growth. This result was consistent with a U87MG
intracranial xenograft study in which mice receiving a combina-
tion of A6 and cisplatin exhibited a significantly greater inhibition
of tumor growth (98%) when compared to either A6 (44%) or
cisplatin (82%). In this study, the combination therapy also sig-
nificantly increased survival time over that for either drug alone.
This was consistent with subcutaneous xenograft results.
Melanoma
The well-characterized B16-F10 lung metastatic model was
employed to determine the ability of A6 to inhibit the coloniza-
tion of secondary tissues by circulating cancer cells (14). B16-F10
melanoma cells were evaluated by flow cytometric analysis and
were shown to express CD44. The IC50 for A6 inhibition of chemo-
taxis in B16-F10 cells was 29 nmol/L, indicative of a responsive cell
line. Melanoma cells were injected into the tail veins of C57BL/6
mice to simulate a burden of metastasizing cells and the lungs were
then evaluated for lesions at day 11. Treatment with A6 reduced the
number of lung metastases to 50% of control. Taken with previous
results, this is important because it demonstrates that A6 not only
inhibits the initial steps of the metastatic process (e.g., migration
and invasion) but also inhibits the formation of secondary lesions
after tumor cells enter the circulation.
Leukemia
A6 has also been evaluated for activity in hematological malignan-
cies. Chronic lymphocytic leukemia (CLL) is characterized by the
accumulation of mature monoclonal B cells in the blood and sec-
ondary tissues. CD44 is highly expressed in CLL cells and mediates
the interaction between CLL cells and the microenvironment. CLL
cells receive survival signals from the microenvironment, and one
of these pathways is mediated by CD44. Binding of HA to CD44
has been shown to activate PI3K/AKT and MAPK/ERK-mediated
survival pathways, and to induce expression of the anti-apoptotic
protein Mcl-1, which promotes CLL cell survival (28). It has been
shown that this effect can be blocked by an inhibitor of Mcl-
1, or by anti-CD44 monoclonal antibodies, leading to apoptosis
in vitro (29, 30).
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Recent studies (31, 32) with human CLL B-cell lymphocytes
have shown that A6 down modulates the expression of CD44
and ZAP-70 (a marker for an aggressive form of CLL), and
inhibits B-cell receptor (BCR) signaling, resulting in a direct,
dose-dependent, cytotoxicity in vitro. To evaluate the effects of
A6 in vivo, an established CLL xenograft model was employed.
ZAP-70pos B-cell lymphocytes isolated from individual patients
were injected into immune-deficient mice treated with A6 or vehi-
cle control. A6 treatment resulted in up to 90% reduction in CLL
burden (31, 32). Previously, A6 had not demonstrated cytotoxi-
city in solid tumor models of glioma, breast, and ovarian cancer
(14, 22, 23, 25). However, in these CLL studies, A6 was shown to
be directly cytotoxic for CLL B-cell lymphocytes. A6 is currently
being evaluated for the treatment of CLL.
CLINICAL STUDIES
Several clinical studies have been conducted to evaluate the safety
and efficacy of A6. These include safety studies in healthy volun-
teers as well as studies in patients with varying stages of metastatic
disease.
Normal volunteers
A6 was administered to normal volunteers in a Phase 1a, double-
blind, placebo-controlled, parallel-group clinical trial (33). Results
showed that there were no systemic drug-related adverse events.
No significant alterations in physical examinations, vital signs,
electrocardiograms, or clinical laboratory testing, including coag-
ulation parameters such as PT, PTT, fibrinogen, and thrombin
time, were noted. Pharmacokinetic data in normal volunteers at
the 150 and 300 mg/day single dose levels showed a t 1/2 of 1.8–
2.0 h at both dose levels. Furthermore, no cumulative increase
in concentration over time was detected. Following A6 subcuta-
neous administration twice daily for 6 days, no anti-A6 antibody
production was detected at day 14 (33).
Advanced gynecologic cancer
A Phase 1b trial was conducted in women with advanced gyne-
cologic cancer (34). Greater than 40% of patients dosed contin-
uously with A6 experienced disease stabilization. The study used
a sequential dose-escalation design, with the lowest-dose group
(four patients) receiving A6 for cycles of 14 days “on” followed by
14 days “off,” a regimen not expected to produce any therapeutic
effect. Twelve patients with advanced gynecologic malignancies
that had failed standard therapy were treated with daily, unin-
terrupted A6. In this population, in which disease progression is
expected, five patients (four of whom had ovarian or primary
peritoneal carcinoma) achieved stable tumor measurements for
at least 4 months, and one for greater than 12 months. Patients
continued treatment until disease progression or unacceptable
toxicity. Response was evaluated as defined by RECIST and the
Gynecologic Cancer Intergroup (GCIG) CA-125 response criteria.
A Kaplan–Meier retrospective analysis demonstrated that patients
treated with daily A6 showed a delayed time to tumor progres-
sion relative to an effective control group (whose treatment was
intermittent and, therefore, not expected to have beneficial effect)
providing evidence of antineoplastic activity. Continuous treat-
ment with A6 resulted in an increased TTP with a median TTP
of 78 days (95% CI 57, 365) compared to 44 days (95% CI 4, 62)
in patients who received the intermittent therapy (log-rank p-
value= 0.02). The safety outcome in this Phase 1b gynecologic
cancer trial was excellent and showed no specific toxicity profile.
Asymptomatic progression of ovarian cancer
A randomized, double-blind, placebo-controlled Phase 2 clinical
trial evaluating A6 in women with asymptomatic CA-125 pro-
gression of ovarian cancer (“marker-only relapse” or MOR) was
conducted (35). Patients were in clinical remission after first-
line chemotherapy with no evidence of disease following physical
examination or imaging analysis, but had two consecutive, above-
normal, increases of CA-125 (a biomarker for recurrence/poor
prognosis). Because patients were clinically asymptomatic at the
time of entry, the study was able to be placebo-controlled. The
primary endpoints were time to clinical progression of disease
and safety of A6. The secondary endpoints included changes in
serum CA-125. This study enrolled 24 patients: 12 were ran-
domized to daily self-administration of A6 at two doses, and
12 to matching placebo injections. Both groups were followed
for up to 9 months. Although there were no complete responses,
36% of patients achieved stable disease. A6 treatment was not
associated with CA-125 response. Results from a Kaplan–Meier
analysis of progression-free survival (PFS) showed that treatment
with A6 significantly prolonged TTP. Despite the small patient
sample size, A6 therapy was associated with a statistically signif-
icant increase in PFS (log-rank p-value= 0.01) with a median
PFS of 100 days (95% CI 64, 168) compared to 49 days (95% CI
29, 67) in patients who received the placebo. Furthermore, the
safety profile of A6 was comparable to that of control (placebo)
treatment.
Persistent or recurrent ovarian cancer
A Phase 2 trial was conducted in patients with persistent or
recurrent epithelial ovarian, fallopian tube, or primary peri-
toneal carcinoma (36) to evaluate A6 in a patient population
with a disease burden greater than that presented in the pre-
viously described MOR trial. Patients had received one prior
platinum-based chemotherapeutic regimen and were allowed to
have received one additional cytotoxic regimen for the manage-
ment of recurrent or persistent disease. Patients received a 150 mg
twice daily subcutaneous dose of A6 and continued on treat-
ment until disease progression or unacceptable toxicity. Response
criteria were as defined by RECIST. Primary measures of clini-
cal efficacy were objective tumor response and PFS at 6 months
compared to a historical Gynecologic Oncology Group (GOG)
dataset based on a similar population of patients. Of the 31 eligible
patients evaluated, no responses were observed; 6.5% were pro-
gression free for at least 6 months; and 36% of evaluable patients
achieved stable disease. A6 was well tolerated but had minimal
activity in patients with persistent or recurrent epithelial ovarian,
fallopian tube, or primary peritoneal carcinoma under the con-
ditions of this trial. Considering the relationship of A6 to CD44
and the relationship of CD44 to resistant and recurrent disease, it
would be of interest to follow this study with a combination trial
comparing standard-of-care to standard-of-care plus A6 in this
difficult population.
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A6 AND OCULAR DISEASE
A6 has been evaluated for the treatment of ocular disease (37).
The focus of this application has been wet age-related macular
degeneration (AMD) and diabetic retinopathy, which are char-
acterized by neovascularization and vascular permeability. Since
angiogenesis is known to involve HA and to be mediated by CD44
(38–40), A6 has been investigated for use as a therapeutic for
these conditions. Angiogenesis is a multistage process involving
cell migration and ECM remodeling, including the loss of cellu-
lar structure and function followed by invasion. Similar cellular
changes are also observed early in the metastatic process. These
cellular changes can be more accurately described in terms of an
epithelial–mesenchymal transition (EMT). EMT is a process by
which epithelial cells acquire mesenchymal-like properties, with
reduced intercellular adhesion and increased motility, critical to
many developmental, homeostatic, and pathological processes.
The EMT process is a continuum leading to enhanced cell migra-
tion and invasion. Preceding migration, there is a loss of cadherin
and epithelial adhesion, followed by disruption of the basement
membrane and degradation of the ECM by MMPs (41–45). A6
has been shown to inhibit this process.
WET AGE-RELATED MACULAR DEGENERATION
Several in vivo studies have been conducted to evaluate the efficacy
of A6 for the treatment of wet AMD. In the mouse model of laser-
induced choroidal neovascularization (CNV), treatment with A6
resulted in a 95% inhibition of new vessel formation compared to
the non-treated control group (46). Results employing a rat model
of laser-induced CNV showed that subcutaneous injections of A6
produced a 70% reduction in CNV compared to non-treated con-
trols (47). Finally, results from a primate model of laser-induced
CNV demonstrated that intravitreal administration of A6 resulted
in a 71% reduction in CNV relative to control (48). These stud-
ies demonstrate that A6 may be a promising candidate for the
treatment of wet AMD.
DIABETIC RETINOPATHY
Research involving the use of A6 for treatment of diabetic retinopa-
thy demonstrated that A6 treatment prevents the loss of vascular
endothelial (VE)-cadherin and inhibits the increase in microvas-
cular permeability in the retina of diabetic Brown Norway rats
induced with streptozotocin (49). In the same study, similar results
were observed using bovine retinal microvascular endothelial cells
and showed that VE-cadherin degradation was associated with
increased vascular permeability and the secretion and activation
of MMP-2 and MMP-9. Treatment with A6 was shown to inhibit
MMP-dependent VE-cadherin degradation and the loss of per-
meability. In addition, A6 prevented the secretion and activation
of MMP-2 and MMP-9 (49). HA has also been shown to increase
MMP-2 and MMP-9 expression in cell culture (50) and to pro-
mote CD44-EGFR interaction leading to MMP-2 secretion and
enhanced cell motility (51). The ability of A6 to inhibit MMP
activation may have important implications for the metastatic
process.
The role of hepatocyte growth factor (HGF) in angiogene-
sis (52, 53) as well as the elevated intravitreous concentrations
of HGF in diabetic patients has been described (54, 55). The
effect of A6 on HGF and its receptor, c-Met, in retinal angiogen-
esis has been examined (56). This study demonstrated that HGF
was upregulated in the retinas of mice following hypoxia-induced
retinal neovascularization. Furthermore, HGF was shown to stim-
ulate retinal microvascular endothelial cell invasion in vitro, which
is consistent with the angiogenic process. HGF-induced retinal
endothelial cell invasion was reduced to control levels following
treatment with A6 (56). Since CD44 functions as a co-receptor
with c-Met, these results suggest a possible mechanistic pathway
for A6.
DISCUSSION
The metastatic process involves migration and invasion of tumor
cells from the local microenvironment, intravasation into the
blood or lymph circulation, extravasation from circulation back
into tissue, followed by metastatic colonization and growth or dor-
mancy (57). Metastasis and recurrence have been linked to a sub-
population of highly invasive tumorigenic cells, which have been
shown to be resistant to chemotherapeutics. These tumorigenic
cells are characterized by the expression of CD44, a multifunc-
tional receptor involved in cell signaling, adhesion, migration, and
proliferation. CD44 functions as a receptor, as a co-receptor (e.g.,
c-Met and EGFR), and as a platform for MMPs to enable many bio-
logical processes (58, 59). In addition, CD44 is known to mediate
invasion and metastasis (60).
Chemotherapeutic resistance has been linked to a number of
CD44 pathways including MDR1-dependent efflux of chemother-
apeutics (61–65). This resistance results in expansion of invasive
cells following first-line chemotherapy, which leads to recurrence.
Studies have shown that targeting CD44 or related signaling path-
ways, using RNAi strategies (61, 62, 66, 67) or with anti-CD44
antibodies (68), will suppress tumor growth and relapse, and
increase sensitivity of these cells to chemotherapeutics. In animal
xenograft models, A6 has been found to enhance the activities of
both tamoxifen to inhibit the growth of breast tumor cell growth
(24) and cisplatin to inhibit the growth of glioma cells (26). This
supports the concept that targeting CD44 may render tumor cells
more sensitive to therapeutic agents.
A6 has been shown to bind to CD44 and to modulate CD44-
mediated activity. A6 demonstrates anti-metastatic properties by
inhibiting migration and invasion, which are early steps in the
metastatic process. The mechanism by which A6 acts may involve
inhibition of EMT, as observed in studies of ocular disease where
A6 inhibited MMP activation and cadherin degradation (49).
Rationale for this consideration is supported by evidence that HA
is implicated in MMP activation (50, 51). A6 also acts later in
the metastatic process to inhibit the formation of lesions resulting
from the direct injection of cancer cells into the blood stream (14).
This would indicate that A6 inhibits steps involving extravasation
and/or metastatic colonization. This is important when consider-
ing recurrence following adjuvant therapy and the possibility of
proliferation of dormant micrometastases long term.
Dormancy and micrometastases present a therapeutic chal-
lenge (69, 70). That subclinical micrometastases may be present
long-term was demonstrated in a study involving 36 breast can-
cer patients found to be disease free from 8 to 22 years post-
resection (71). This study demonstrated that in one-third of these
www.frontiersin.org March 2015 | Volume 6 | Article 135 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finlayson Modulation of CD44 activity by A6-peptide
patients, with no evidence of disease, viable circulating tumor
cells (CTCs) could be isolated. The CTCs were determined to
be non-proliferative with a short half-life, but were found when
repeated samples were taken up to 2 years after the patients entered
the study. This suggested that CTCs were being continuously
released from subclinical micrometastases. Long-term or main-
tenance therapy targeting recurrence is not practical when consid-
ering many cytotoxic agents. However, due to its superior safety
profile (no immunogenicity, no dose-limiting toxicities, no seri-
ous side-effects), long-term or maintenance therapy with A6 may
be an option. The use of A6 in this manner could introduce a new
paradigm to cancer treatment.
As previously noted, A6 shares sequence homology with the
link module of CD44. The link module of CD44 has been shown
to be critical to HA binding and cell migration. When the CD44
link module was substituted with a homologous region of higher
HA affinity (TSG-6), cells expressing this chimera bound HA,
but failed to migrate and were described as tethered (20). A6
was shown to increase the binding of CD44-expressing SKOV3
cells to HA-coated plates (14). This effect was blocked with the
anti-CD44 antibody, IM7. However, neither A6 nor IM7 had any
effect on the binding of CD44-non-expressing A2780 cells to HA-
coated plates. These results suggest that increasing adhesion may
play a role in the anti-metastatic activity of the A6-peptide, and
again illustrate correlation of A6 activity with CD44 expression.
The study further demonstrated that A6 perturbed the binding
of the anti-CD44 antibody, DF1485, to CD44-expressing SKOV3
cells. This was reported to be a partial inhibition, which did not
result from a competition involving either A6 or CD44. Fur-
thermore, the DF1485 antibody did not recognize A6 or inhibit
the binding of an anti-A6 antibody to A6. It was postulated
that A6 induces conformational changes in CD44, resulting in
either a lowered affinity of the epitope for DF1485, or prevent-
ing DF1485 from binding (14). Regardless of the mechanism,
the binding of A6 to CD44 results in a modulation of CD44-
mediated intracellular signaling (14). This establishes a functional
relationship between A6 and CD44 in CD44-expressing cells. This
functional relationship was demonstrated by monitoring FAK
phosphorylation in the presence and absence of A6 and HA in
CD44-expressing and -non-expressing cell lines. Although HA
is reported to have a rheostatic effect on CD44, with high mol-
ecular weight HA inhibiting tumor progression, and low mol-
ecular weight HA stimulating tumor progression (72–74), the
extent to which A6 may differentiate these activities has yet to
be studied.
The precise mechanism of A6 has not been defined, but com-
pelling evidence from studies on metastatic and ocular disease
supports action through a CD44-mediated pathway. Whether this
is by direct action on CD44 or by modulating CD44 co-receptor
activity remains unclear. A6 binding to CD44 and the effects of A6
on chemotaxis and intracellular signaling have been demonstrated
in the absence of HA. This indicates that A6 has a primary effect,
through CD44, that is independent of HA. However, because A6
increases adhesion of CD44-expressing cells to HA, it also suggests
that A6 may interact with HA secondarily to A6 binding to CD44.
The CD44 ligand-binding region that shares homology with A6 is
likely to be critical to the mechanism by which A6 modulates the
activity of CD44. A6 may simulate the CD44 sequence and trigger a
homotypic interaction resulting in modification of CD44 activity
by inducing a conformational change in CD44, or CD44 dimeriza-
tion, or both. As mentioned, the perturbation of DF1485 binding
by A6 suggests that A6 may induce conformational changes in
the receptor. Alternatively, A6 homology may simulate the CD44
sequence permitting it to influence a CD44-binding partner/co-
receptor resulting in modulation of CD44-mediated activity. This
is supported by A6 inhibitory activity on HGF and MMPs observed
in ocular diseases. Finally, although A6 binds to CD44, the pos-
sibility cannot be excluded that A6 interacts with a protein inde-
pendent of CD44 that initiates secondary modulation of CD44
activity.
CD44 is a complex multifunctional receptor modulating a vari-
ety of cellular processes. Although the mechanistic process is not
completely defined, the studies described have demonstrated that
A6 inhibits the metastatic process in a CD44-dependent man-
ner. Because CD44 is associated with a chemoresistant phenotype,
which is countered by inhibition of CD44 signaling, A6 is a can-
didate for inhibition of CD44-mediated resistance. In this case,
A6 would be used in combination with a cytotoxic chemother-
apeutic agent to inhibit metastases and to render resistant cells
sensitive to chemotherapy. Certainly, the results from preclini-
cal A6 combination studies in animals support this approach.
Furthermore, due to the positive safety profile documented for
A6, there would be a reduced likelihood of compounding toxi-
city. As such, A6 may potentially be combined with almost any
chemotherapeutic. This safety profile also invites the use of A6
for longer-term maintenance therapy to prevent recurrence stem-
ming from micrometastases surviving first-line standard-of-care
treatment. A6 has demonstrated activity against CD44-expressing
tumor cells and CLL cells, and is a candidate for the treatment of
malignant disease and hematological malignancy. A6 has demon-
strated clinical safety and efficacy, and by targeting CD44-resistant
cells to prevent metastases and recurrence, has the possibility of
creating a new paradigm for cancer treatment.
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